The patient’s clinical diagnosis was not supported by the analysis of WD metabolic markers, cerebrospinal fluid (CSF) biomarkers, dopamine transporter SPECT [88], or amyloid/tau PET imaging, which could have helped to further elucidate the etiology [89]. The gene discussed is MAPT; the disease is Wilson disease.